Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization

被引:156
作者
Berger, M
Bergers, G
Arnold, B
Hämmerling, GJ
Ganss, R
机构
[1] German Canc Res Ctr, Dept Mol Immunol, D-69120 Heidelberg, Germany
[2] Univ Calif San Francisco, Ctr Comprehens Canc, BTRC, Dept Neurol Surg, San Francisco, CA 94143 USA
关键词
D O I
10.1182/blood-2004-06-2315
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We identified regulator of G-protein signaling-5 (RGS-5) as an angiogenic pericyte marker at sites of physiologic and pathologic angiogenesis. In a mouse model of pancreatic islet cell carcinogenesis, RGS-5 is specifically induced in the vasculature of premalignant lesions during the "angiogenic switch" and further elevated in tumor vessels. Similarly, RGS-5 is over-expressed in highly angiogenic astrocytomas but not in hypoxia-inducible factor-1alpha (HIF-1alpha)-deficient tumors, which grow along preexisting brain capillaries without inducing neovessels. Elevated levels of RGS-5 in pericytes are also observed during wound healing and ovulation indicating a strong correlation between RGS-5 expression and active vessel remodeling beyond tumor angiogenesis. Moreover, antitumor therapy, which reverses tumor vasculature to an almost normal morphology, results in down-regulation of RGS-5 transcription. Taken together, these data demonstrate for the first time a factor that is specific for "activated" pericytes. This further supports the notion that pericytes, like endothelial cells, undergo molecular changes during neovascularization that makes them a novel target for antiangiogenic therapy. (C) 2005 by The American Society of Hematology.
引用
收藏
页码:1094 / 1101
页数:8
相关论文
共 42 条
  • [1] Bell SE, 2001, J CELL SCI, V114, P2755
  • [2] Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
    Benjamin, LE
    Golijanin, D
    Itin, A
    Pode, D
    Keshet, E
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (02) : 159 - 165
  • [3] Benjamin LE, 1998, DEVELOPMENT, V125, P1591
  • [4] Tumorigenesis and the angiogenic switch
    Bergers, G
    Benjamin, LE
    [J]. NATURE REVIEWS CANCER, 2003, 3 (06) : 401 - 410
  • [5] Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
    Bergers, G
    Javaherian, K
    Lo, KM
    Folkman, J
    Hanahan, D
    [J]. SCIENCE, 1999, 284 (5415) : 808 - 812
  • [6] Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
    Bergers, G
    Song, S
    Meyer-Morse, N
    Bergsland, E
    Hanahan, D
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) : 1287 - 1295
  • [7] The hypoxic response of tumors is dependent on their microenvironment
    Blouw, B
    Song, HQ
    Tihan, T
    Bosze, J
    Ferrara, N
    Gerber, HP
    Johnson, RS
    Bergers, G
    [J]. CANCER CELL, 2003, 4 (02) : 133 - 146
  • [8] Transcription profiling of platelet-derived growth factor-B-deficient mouse embryos identifies RGS5 as a novel marker for pericytes and vascular smooth muscle cells
    Bondjers, C
    Kalén, M
    Hellström, M
    Scheidl, SJ
    Abramsson, A
    Renner, O
    Lindahl, P
    Cho, HS
    Kehrl, J
    Betsholtz, C
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (03) : 721 - 729
  • [9] Regulation of chemotactic and proadhesive responses to chemoattractant receptors by RGS (Regulator of G-protein Signaling) family members
    Bowman, EP
    Campbell, JJ
    Druey, KM
    Scheschonka, A
    Kehrl, JH
    Butcher, EC
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (43) : 28040 - 28048
  • [10] Carson-Walter EB, 2001, CANCER RES, V61, P6649